Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal
blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can
leak fluid into the retina. The build-up of fluid (edema) under the macula can distort vision
or cause vision loss. TG100801 is a topical (eye drop) therapy that has been shown to inhibit
ocular angiogenesis, vascular leak, and inflammation in laboratory studies. The primary
purpose of this pilot study is to evaluate the ability of topical administration of TG100801
to reduce the amount of fluid in the retina in patients with AMD following 30 days of
treatment. An additional objective is to evaluate the safety of TG100801 in patients with
AMD.